ClinicalTrials.gov
ClinicalTrials.gov Menu

Investigation Into the RAtio of LDL-CHolestEroL to HDL-Cholesterol Improvement After Statin Treatment in Korean Patients (RACHEL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00931320
Recruitment Status : Completed
First Posted : July 2, 2009
Last Update Posted : October 27, 2009
Sponsor:
Information provided by:
AstraZeneca

Brief Summary:
An observational, non-interventional, multi-centre study to provide further information on the ratio of LDL-C to HDL-C improvement after statin treatment in Korean patients group.

Condition or disease
Dyslipidemias

Study Type : Observational
Estimated Enrollment : 3000 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Investigation Into the RAtio of LDL-CHolestEroL to HDL-Cholesterol Improvement After Statin Treatment in Korean Patients
Study Start Date : July 2009
Actual Study Completion Date : September 2009


Group/Cohort
3000 patients
Who have at least made 1 visit to the outpatient clinic within previous 6 months .



Primary Outcome Measures :
  1. Evaluate current LDL/HDL ratio in Korean patients (between baseline & after treatment) [ Time Frame: After Treatment : at least 4 weeks before statin taking /Baseline : no limitation. ]

Secondary Outcome Measures :
  1. Evaluate difference of LDL/HDL ratio among different statins & dosages (between baseline & after treatment) [ Time Frame: After Treatment : at least 4 weeks before statin taking / Baseline : no limitation. ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Who have at least made 1 visit to the outpatient clinic within previous 6 months .
Criteria

Inclusion Criteria:

  • Subjects who are taking lipid-lowering medication after diagnosed as dyslipidaemia
  • Subjects who have at least made 1 visit to the outpatient clinic within previous 6 months
  • Subjects who have records of both LDL-C and HDL-C before & after statin treatment (at least four weeks after statin taking)

Exclusion Criteria:

  • Subjects who are unwilling or unable to provide their examination and lab result of medical chart.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00931320


Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Hyunah Caroline Choi AstraZeneca Korea

Responsible Party: Hyunah Caroline, Choi / CV TA Physician, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00931320     History of Changes
Other Study ID Numbers: NIS-CKR-DUM-2009/3
First Posted: July 2, 2009    Key Record Dates
Last Update Posted: October 27, 2009
Last Verified: October 2009

Keywords provided by AstraZeneca:
Ratio improvement
LDL-C
HDL-C
Ratio of Low Density Lipoprotein Cholesterol to High Density Lipoprotein Cholesterol Improvement
High Density Lipoprotein Cholesterol

Additional relevant MeSH terms:
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases